Pfizer's orphan drug Vyndamax passes drug review panel for reimbursement
Vyndamax (tafamidis), a drug to treat the rare disease transthyretin amyloid cardiomyopathy (ATTR-CM), and Qarziba (dinutuximab beta), a drug to treat neuroblastoma, have finished 80 percent of the reimbursement process. Darzalex (daratumumab) for multiple …